816-LAW-FIRM or 800-305-7552
Pharmaceutical Litigation
 
Avandia
 
Gadolinium
 
Ortho Evra
 
OTC Cough and Cold
 
Provigil
 
Tequin
 
Trasylol
 
Vioxx
 
Vytorin
 
Zelnorm
  More
Medical Devices
 
Ancure Endograft Stents
 
Breast Implants
 
Composix Kugel Mesh Patch
 
Gambro
 
Knee Replacements
 
Smith & Nephew Implants
 
St. Jude Aortic Connector
 
Sulzer Hip
 
Volumetric Infusion Pumps
Personal Injury
 
Airplane Crashes
 
Burn Injuries
 
Head & Brain Injuries
 
Railroad Crossing Accidents
 
Spinal Cord Injuries
 
Trucking Accidents
Nursing Home Litigation
 
Bedsores and Decubitus Ulcers
 
Elder Abuse
 
Falls/Fractures
 
Malnutrition/Dehydration
 
Nursing Homes
 
Wrongful Death
Toxic Chemicals/Environmental
 
Asbestos
 
Benzene
 
Popcorn Packer's Lung Disease
 
Silica
 
Trichloroethylene (TCE)
 
Welding Rods
Defective/Recalled Products
 
Airbags
 
Firestone Tires
 
SUV Rollovers
 
Tobacco
Medical Malpractice
 
Birth Injuries
 
Failure To Promptly Diagnose Cancer, Heart Disease or Other Diseases
 
Other Malpractice Claims
 
Surgical Complications
Consumer Protection
 
Unum Provident Denial Of Benefits
Securities and Investor Fraud
 
WorldCom
  More
Lamisil

Click Here For A Free Case Evaluation

Manufacturer: Glaxo Wellcome Inc.
Uses: Sporanox® Capsules and Lamisil® Tablets are prescription medicines approved to treat toe and finger nail fungal infections. Sporanox® Capsules, Oral Solution, and Injection are also approved to treat serious fungal infections that may occur in other parts of the body.
Lamisil® is also available as cream and solution.
More Information
Lamisil Tablets
Lamisil Tablets

The FDA issued a Public Health Advisory to announce important safety-related updates to the labeling of Sporanox® (itraconazole) and Lamisil® (terbinafine hydrochloride) Tablets.

FDA is advising healthcare professionals not to prescribe Sporanox® to treat fungal infections (onychomycosis) in patients who have congestive heart failure (CHF) or a history of CHF. The updated Sporanox® labeling also includes contraindications and precautions with certain medicines.

FDA's advisory also alerts the public that both Sporanox® and Lamisil® Tablets have been associated with serious liver problems including liver failure and death.

  • As of March 2001, the FDA has reviewed 24 cases of liver failure possibly associated with Sporanox® use, including 11 deaths.
  • As of April 2001, FDA has reviewed 94 cases in which Sporanox® treated patients developed congestive heart failure. In 58 of the 94 cases, FDA believes Sporanox® contributed to or may have been the cause of the congestive heart failure. Although the causal relationship is unclear, death was reported in 13 cases.
  • As of April 2001, the FDA has reviewed 16 possible Lamisil® associated cases of liver failure, including 11 deaths and two liver transplant patients.

Side Effects
Some warning signs of congestive heart failure:
  • Shortness of breath
  • Swelling of the feet, ankles, legs, or abdomen
  • Weight gain
  • Unusually tired
  • Coughing up of white or pink mucous
  • Unusual fast heartbeats


  • Some warning signs of liver failure:
  • Nausea
  • Vomiting
  • Abdominal pain
  • Fatigue
  • Loss of appetite
  • Dark urine
  • Generalized skin discoloration

  • Resources

    Featured Articles

    Click Here For A Free Case Evaluation



    © 2007, Peterson & Associates, P.C.
    Past results afford no guarantee of future results and each case is different and is judged on its own merits. Some cases result in no recovery. Costs and expenses will be advanced and reimbursed to us only if you recover. You have no liability for costs or expenses unless a court directs. The choice of a lawyer is an important decision and should not be based solely upon advertisements. Some matters may be referred to other lawyers. Neither the Supreme Court of Missouri nor the Missouri Bar reviews or approves certifying organizations or specialist designations. Never stop taking any prescription drug without first consulting with a doctor.
    View Our Full Disclaimer